NVO Jan 2025 175.000 put
| Previous close | 45.70 |
| Open | 45.70 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 175.00 |
| Expiry date | 2025-01-17 |
| Day's range | 45.70 - 45.70 |
| Contract range | N/A |
| Volume | |
| Open interest | 142 |
- Yahoo Finance Video
Novo Nordisk slides while Moderna pops: Tale of two pharma stocks
Pharmaceutical stocks Novo Nordisk (NVO) and Moderna (MRNA) are trending in opposite directions following their earnings reports. Despite topping Wall Street's profit expectations, Novo Nordisk shares are sinking as the company fell short of estimates for its popular GLP-1 weight-loss drug, Wegovy. Meanwhile, Moderna is on the rise even after reporting first quarter losses. Moderna's growth is largely due to an uptick in coronavirus boosters and an expansion into the Brazillian market. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl
Yahoo FinanceNovo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
ReutersNovo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Novo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the day. Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide, which, if approved, would compete Novo's Wegovy and Eli Lilly's Zepbound. "Novo's share price today is certainly factoring in some negative reaction to Amgen's positive commentary on MariTide development yesterday," Kepler Cheuvreux analyst David Evans said, but added that "a continued negative reaction to results and pricing concerns yesterday is likely also a smaller part of the move today".
